Condition: Neoplasms, Prostate · Sponsor: GlaxoSmithKline
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | La Jolla, California, United States | Recruiting |
| GSK Investigational Site | Grand Rapids, Michigan, United States | Recruiting |
| GSK Investigational Site | Philadelphia, Pennsylvania, United States | Recruiting |
| GSK Investigational Site | West Valley City, Utah, United States | Recruiting |
| GSK Investigational Site | Melbourne, Victoria, Australia | Recruiting |
| GSK Investigational Site | Toronto, Ontario, Canada | Recruiting |
| GSK Investigational Site | Montreal, Quebec, Canada | Recruiting |
| GSK Investigational Site | Tokyo, Japan | Recruiting |
| GSK Investigational Site | Tokyo, Japan | Recruiting |
| GSK Investigational Site | Seoul, Seoul Teugbyeolsi, South Korea | Recruiting |
| GSK Investigational Site | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.